We believe Aspen’s (APN) current manufacturing and supply woes are self-inflicted. The global recurring shortages of APN’s key products will not only put a damper on revenue but might pose reputational risk to APN as the preferred supplier of critical medicines. Although growth in China seems promising, we are still of the view that operating conditions in the country are complex and favour local manufacturers.
